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We report a novel approach to bonemarrow (BM) conditioning
using c-kit-targeted chimeric antigen receptor T (c-kit CAR-T)
cells in mice. Previous reports using anti-c-kit or anti-CD45
antibody linked to a toxin such as saporin have been promising.
We developed a distinctly different approach using c-kit CAR-T
cells. Initial studies demonstrated in vitro killing of hematopoi-
etic stem cells by c-kit CAR-T cells but poor expansion in vivo
and poor migration of CAR-T cells into BM. Pre-treatment of
recipient mice with low-dose cyclophosphamide (125 mg/kg)
together with CXCR4 transduction in the CAR-T cells enhanced
trafficking to and expansion in BM (<1%–13.1%). This resulted
in significant depletion of the BM c-kit+ population (9.0%–
0.1%). Because congenic Thy1.1 CAR-T cells were used in the
Thy1.2-recipient mice, anti-Thy1.1 antibody could be used to
deplete CAR-T cells in vivo before donor BM transplant. This
achieved 20%–40% multilineage engraftment. We applied this
conditioning to achieve an average of 28% correction of chronic
granulomatous disease mice by wild-type BM transplant. Our
findings provide a proof of concept that c-kit CAR-T cells can
achieve effective BM conditioning without chemo-/radio-
therapy. Our work also demonstrates that co-expression of a
trafficking receptor can enhance targeting of CAR-T cells to a
designated tissue.
INTRODUCTION
Hematopoietic stem cell (HSC) transplantation is one of the curative
therapeutic options for patients with a variety of inherited disorders
of blood cells, including immune deficiencies and hemoglobinopa-
thies.1–3 In addition, considerable progress has been made toward
achieving clinical benefit from autologous HSC ex vivo gene therapy
for some of these disorders.3,4 In general, some level of bone marrow
(BM) conditioning using chemotherapy and/or radiation is needed to
achieve the required engraftment of allogeneic HSC or gene-corrected
autologous HSC. There is considerable interest in finding less toxic
and more focused approaches to achieve BM conditioning. Promising
results have been observed using antibody-based approaches
including anti-c-kit (CD117)5,6 or anti-CD45 antibodies,7 which
directly target HSCs. Results with anti-c-kit antibody were enhanced
in combination with anti-CD47 antibody,8 and those with anti-CD45
antibody were greatly enhanced by conjugation to saporin.9 Here we
explored a related, but distinct, approach in immunocompetent
congenic mice using c-kit-targeted chimeric antigen receptor
T (c-kit CAR-T) cells to deplete HSCs in BM, thereby enabling donor
BM engraftment.
As noted, there is considerable work published about antibody-based
approaches targeting either c-kit or CD45 on the surface of HSCs or
progenitors.8,9 C-kit is a dimeric transmembrane receptor tyrosine
kinase expressed by HSCs and downstream progenitors,10 and
c-kit-ligand signaling through this receptor is essential for HSC
homing, proliferation, adhesion, maintenance, and survival.11,12 On
the other hand, CD45 is a cell surface glycoprotein with tyrosine
phosphatase activity expressed exclusively on all hematopoietic cells
including HSCs, with the exception of platelets and erythrocytes.13
CD45 participates in the regulation of lymphocyte activation and
maturation, as well as thymic selection.14
Rat anti-mouse c-kit monoclonal antibody (ACK2) was first reported
in 2007 to achieve targeted reduction in HSCs sufficient to allow
donor BM engraftment in Rag2/ gc/ immunodeficient mice.5
For this approach to work in T cell-immunocompetent mice required
a modest dose (3 Gy) of total body radiation.6 Conditioning of immu-
nocompetent mice with c-kit antibody combined with anti-CD47
antibody achieved similar BM conditioning without the need for ra-
diation.8 In this setting, CD47 antibody worked as a myeloid-specific
immune checkpoint inhibitor (CD47 acting as a phagocyte “don’t eat
me” signal15). Unmodified anti-CD45 antibody also required radia-
tion (8 Gy) to achieve effective transplant of allogeneic donor
HSCs.7 However, anti-CD45 antibody conjugated with saporin, a
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catalytic N-glycosidase ribosome-inactivating protein that halts
protein synthesis,16 effectively depleted HSCs to achieve a high level
of congenic donor engraftment in immunocompetent mice without
the need for radiation.9 While additional stepwise improvements of
these antibody-conditioning approaches alone may achieve the
ultimate clinical goal of effective BM conditioning without use of
any radiation or high-dose chemotherapies, the goal for our study
was to explore a related novel approach to BM conditioning using
CAR-T cells. If we could demonstrate a proof of concept that
CAR-T cells that target HSCs can achieve effective BM conditioning
with enhanced donor HSC engraftment, this would add to the list of
tools for further development that investigators could apply to this
important problem.
CARs are synthetic receptors that target T cells to a specific antigen
and reprogram their function.17,18 CAR-T cells bind surface mole-
cules of target cells through their extracellular antigen-binding
domain (antibody element), leading to activation of target cell cyto-
toxicity via the CAR cytosolic CD3z domain independently of
engagement of the major histocompatibility complex.19 CAR-T cell
studies are rapidly advancing the field of cancer immunotherapy,
especially for acute lymphoblastic leukemia20 and multiple
myeloma.21 The virtues of CAR-T cells are that the cytotoxicity
depends directly on the T cell function, not requiring antibody-
mediated activation of macrophages or phagocytes,22 and that
CAR-T cells autonomously expand in vivo to magnify the therapeutic
effect.23 These characteristics may be advantageous in the use of this
method for BM conditioning, though this approach also requires a
means to remove or inactivate the c-kit CAR-T cells to achieve sub-
sequent donor engraftment. In this paper, we show how to achieve
efficient BM stem cell depletion and subsequent syngeneic donor
engraftment using c-kit CAR-T cells.
RESULTS
Specific Cytotoxicity of c-kit CAR-T Cells against c-kit+ Cell
Lines In Vitro
Immunoglobulin heavy- and light-chain variable region (VH and VL)
of mouse c-kit antibody was connected by 218 linker and inserted into
a second-generation CARg-retrovirus vector construct24 (Figure 1A).
C57BL/6J mouse T cells were transduced with c-kit CAR vector and
analyzed per the schema shown in Figure 1B. Fluorescence-activated
cell sorting (FACS) analyses performed 48 hr after retroviral trans-
duction (day 3) demonstrated that >90% of T cells expressed c-kit
CAR, as determined by cell surface Fab expression (Figure 1C, top
row, middle panel). As a control, we used a previously described
vascular endothelial growth factor receptor (VEGFR)-2 CAR vec-
tor,24 which generated >60% of T cells with VEGFR-2 CAR expres-
sion (Figure 1C, top row, right panel). Specificity of the CAR-T cells
was demonstrated by showing that recombinant c-kit or VEGFR-2
protein bound specifically to its respective CAR-T cell construct.
The recombinant c-kit protein conjugated with Fc was detected
with anti-Fc fluorescent antibody, and it showed specific binding of
c-kit CAR-T cells (Figure 1C, middle row, middle panel). The recom-
binant VEGFR-2 protein conjugated with Fc was also detected with
anti-Fc fluorescent antibody, and it showed specific binding of
VEGFR-2 CAR-T cells (Figure 1C, lower row, right panel). We
explored alternate constructions of c-kit CAR extracellular antibody




finding empirically that the VH-218-VL construct
was most efficient at transduction and expression (Figure S1).
Furthermore, a more detailed time course analysis of CAR expression
detected by anti-Fab (Figure 1D) showed that c-kit CAR or control
VEGFR-2 CAR was detected within 24 hr after the retrovirus vector
transduction with sustained high expression through day 5, followed
by only a modest decrease in the number of cells expressing CAR
through day 10 in vitro.
We evaluated in vitro cytotoxicity of c-kit CAR-T cells toward both
adherent (NIH 3T3 murine fibroblast) and suspension (murine B
cell leukemia E2a-PBX [CD19+]) cell lines that had been transduced
three times with lentivector encoding murine c-kit cDNA to achieve
strong surface expression of c-kit in a significant proportion of cells
within the target lines (Figure 1E, upper panel and lower panels,
respectively). The NIH 3T3 cells (both c-kit naive and c-kit+)
were also transduced with lentivector encoding GFP to facilitate mi-
croscopy visualization of live attached cells. When c-kit+-transduced
cell line targets were co-cultured with c-kit CAR-T cells, c-kit
CAR-T cell binding to c-kit induced activation-mediated generation
of interferon (IFN)g by the CAR-T cells, as detected in supernatant
at 24 hr (two highest bars seen in Figure 1F). Control CAR-T cell
cultures with no target cells present (none), with target cells not
transduced to express c-kit (naive), with use of untransduced
T cells, or with VEGFR-2 CAR-T cells generated little or no IFNg
(Figure 1F). Not shown but previously published is that VEGFR-2
CAR-T cells produce high levels of IFNg when incubated with cell
lines expressing VEGFR-2.24 Cytotoxicity of c-kit CAR-T cells
toward the adherent GFP+c-kit+ NIH 3T3 target in co-culture was
visually confirmed by demonstrating detachment of this target cell
Figure 1. Generation and Evaluation of c-kit CAR-T Cells
(A) Schematic map of c-kit CAR g-retrovirus. (B) Timeline of CAR-T cell production and evaluation. (C) FACS analysis (day 3) of c-kit or VEGFR-2 CAR expression detected by
anti-murine Fab (top row). Specific binding of Fc-conjugated murine c-kit or VEGFR-2 with c-kit CAR or VEGFR-2 CAR was detected with anti-Fc fluorescent antibody
(middle and bottom rows). (D) Time course of c-kit or VEGFR-2 CAR expression (mean ± SD; n = 5; **p < 0.01 compared with mock-transduced T cells). (E) FACS analysis of
c-kit expression on NIH 3T3 or E2a-PBX (CD19+) transduced with c-kit lentivector compared to naive. (F) Generation of IFNg from c-kit CAR-T cells co-cultured with target
lines expressing recombinant murine c-kit (mean ± SD; n = 5; **p < 0.01 comparison as indicated). (G) GFP photomicroscopy images of GFP+ NIH 3T3 (naive or c-kit
transduced) co-cultured 24 hr with T or CAR-T cells as indicated after PBS rinse. (H) FACS analysis at 24-hr co-culture assessing cytotoxicity of c-kit CAR-T cells toward
c-kit+ E2a-PBX that express CD19. Controls include naive T- or VEGFR-2 CAR-T cells. (I) Percentage of the c-kit+ E2a-PBX within the total E2a-PBX remaining at 24 hr in the
cytotoxicity co-cultures, as described for (H) (n = 5; mean ± SD; **p < 0.01).
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line from the culture plate at 24 hr (Figure 1G, bottom row, middle
panel). Control incubations in all the other panels of Figure 1G
showed no cytotoxicity detachment. Cytotoxicity of c-kit CAR-T
cells toward c-kit+ E2a-PBX cells resulted in lysis, as indicated by
the loss of these c-kit+CD19+ target cells from the culture as assessed
by FACS at 24 hr (Figure 1H, middle panel, and Figure 1I, middle
bar). These c-kit+CD19+ E2a-PBX target cells remained intact in
control co-cultures containing untransduced T cells or VEGFR-2
CAR-T cells (Figure 1H, left and right panels, and Figure 1I, left
and right bars, respectively). The larger thin line boxes in the Fig-
ure 1H panels show the percentage of E2a-PBX in culture, and
smaller thick line boxes show the percentage of total culture that
are c-kit+ E2a-PBX. The FACS analysis in Figure 1H is a representa-
tive experiment where the average of 5 experiments is shown in Fig-
ure 1I, where the values indicated for each bar are calculated for each
experiment as the proportion (in percent) of (c-kit+ E2a-PBX)/(total
E2a-PBX) present after co-culture.
In Vitro Depletion of c-kit+ Population in BM Cells and Inhibition
of Colony Formation in Co-culture with c-kit CAR-T Cells
We next assessed c-kit CAR-T cell cytotoxicity toward mouse BM
cells in vitro using T cells and BM from syngeneic C57BL/6J differing
in Thy1 isotype (Thy1.1+ versus Thy1.2+), as indicated in Figure 2A.
FACS analysis shows that about 11% of untreated (naive) C57BL/6J
BMwere c-kit+ (Figure 2B), and it is known that HSC and progenitors
were in this population8 and were mainly CD3 low or negative.
Thy1.1+ naive T cells, c-kit CAR-T cells, or VEGFR-2 CAR-T cells
were incubated with Thy1.2+ BM in the co-culture assay of IFNg
shown in Figure 2C. The number of BM cells was the same in each
culture, but each group differed in the number of T or CAR-T cells
(highest to lowest ratios of T cells relative to BM cells). High levels
of IFNg production proportional to the number of c-kit CAR-T cells
in the culture were detected in the supernatant at 24 hr of incubation
(Figure 2C). Controls (naive T and VEGFR-2 CAR-T cells) as indi-
cated in Figure 2C generated little to no IFNg.
For the same co-culture experiments in which we assessed IFNg gen-
eration, we also assessed depletion of the BM c-kit+ population at
24 hr by FACS analysis (gating on Thy1.2 as shown in Figures 2D
and 2E). At a 1:1 ratio in the culture of Thy1.1 c-kit CAR-T cells
with Thy1.2 BM, there was a significant decrease in the BM c-kit+
population from 11.6% to 2.1% (Figure 2D, left and middle panels).
Inspection of the Figure 2D middle panel dot plot shows almost total
depletion of the cells with high expression of c-kit, where the mean
fluorescence intensity (MFI) of the remaining c-kit+ cells was signif-
icantly lower than the baseline. Total cell viability in the culture dishes
was decreased from 74.9% to 56.7%, which indicated that c-kit
CAR-T cells were also damaged after interaction with c-kit+ BM cells
(Figure 2D, left and middle panels). The amount of decrease of c-kit+
population was dose dependent on the ratio of BM:c-kit CAR-T cells
in the culture (Figure 2E, middle panel). Co-culture controls using
untransduced or VEGFR-2 CAR-T cells had no effect on the BM
c-kit+ population at 24 hr of co-culture (Figures 2D and 2E, left
and right panels or bar sets, respectively).
We next assessed BM colony formation under conditions permissive
of myeloid, erythroid, megakaryocyte, and mixed colony formation.
Pictures shown in Figure 2F are representative colony plate images
from the co-cultures of 1:1 BM:T (or CAR-T cells), where cells
were plated at 24 hr co-culture and assessed 10 days later. No colonies
were evident in the 1:1 BM:c-kit CAR-T cells co-culture plate
(Figure 2F, middle panel), but they are evident in the controls (un-
transduced T or VEGFR-2 CAR-T cells). When multiple experiments
(n = 5) were performed and individual colonies counted, it can be
seen that there was a dose-response effect with respect to the ratio
of BM:c-kit CAR-T cells in the co-culture and that neither untrans-
duced T cells nor VEGFR-2 CAR-T cells had any effect on colony
formation (Figure 2G). At the lower ratios of c-kit CAR-T cells
where some colony formation occurred, the specific ratio of myeloid,
erythroid, megakaryocyte, and mixed colony formation appeared to
be similar to control (data not shown).
Expansion and Trafficking of c-kit CAR-T Cells in BM after
In Vivo Injection
After confirming the specificity and intensity of cytotoxicity of c-kit
CAR-T cells toward c-kit+ HSCs or progenitor cells in vitro, we
performed experiments in vivo using congenic mouse models to
determine expansion and trafficking of c-kit CAR-T cells as per
the timeline in Figure 3A. To assess trafficking by whole-body
imaging, CAR-T cells were generated from luciferase transgenic
mice. Specifically, spleen T cells harvested and CD3 purified from
Thy1.1+CD45.2+luciferase+ transgenic C57BL/6J mice were trans-
duced to produce c-kit CAR-T cells, and 5.0  106 of these cells
were injected via tail vein into Thy1.2+CD45.2+ C57BL/6J mice.
Preliminary studies (data not shown) indicated very poor
expansion of CAR-T cells overall and very little trafficking to BM
when c-kit CAR-T cells were injected without any other maneuvers.
Based on both previous mouse studies with CAR-T cells26,27 and on
human clinical trials using CAR-T cells,20,21 pre-treatment with a
T cell-depleting agent such as cyclophosphamide (CY) appears to
be required to achieve expansion and efficient targeted action
of CAR-T cells. Preliminary to assessing the effect of CY pre-
treatment on CAR-T cell expansion or trafficking, we confirmed
that doses of CY up to 250 mg/kg did not appear to have a measur-
able effect on the mouse BM c-kit+ population or on primitive
long-term repopulating hematopoietic cells known as KSL (c-kit+
sca1+Lineage) that include the most primitive HSC (Figure S2A,
top row).
Using this information, we conducted a series of experiments
following the scheme shown in Figure 3A, where day 1 was harvest
and purification of spleen T cells; day 0 was transduction of T cells
and intraperitoneal (i.p.) injection of CY; and day 1 was intravenous
(i.v.) injection of c-kit CAR-T cells followed by evaluations of periph-
eral blood (PB) count, BM FACS, BM histology, BM colony forma-
tion, and luciferase whole-body imaging on the indicated days. In
initial experiments assessing different dosages of CY pre-treatment,
we found that at least 125 mg/kg was needed to achieve optimal
expansion of CAR-T cells in vivo, but higher doses did not increase
Molecular Therapy
1184 Molecular Therapy Vol. 26 No 5 May 2018
this effect (Figure S2A, middle row). Except where specifically indi-
cated, CY (125 mg/kg) was used in subsequent experiments. In the
studies shown in Figure 3B, the c-kit CAR-T cells generated from
Thy1.1 mice transgenic for luciferase were used. At day 8 after injec-
tion of these luciferase+ Thy1.1 c-kit CAR-T cells, the recipient mice
were injected with luciferin (3 mg/mouse) i.p. and subjected to whole-
body luminescence emission. Emission above the baseline level of
detection was only observed in mice prepared with CY and injected
with the luciferase transgenic c-kit CAR-T cells (Figure 3B; Figure S3).
Despite expansion of the luciferase transgenic c-kit CAR-T cells suf-
ficient to see the luciferase signal, most of the signal was in the region
of the spleen and not in regions expected for BM. Shown in later
experiments below, despite the CY-mediated overall expansion of




Figure 2. Congenic Thy1.1 c-kit CAR-T Cell-Mediated Depletion of HSC from Thy1.2 BM In Vitro
(A) Timeline of CAR-T production and effect on Thy1.2 BM in vitro. (B) FACS analysis of c-kit+ cells in BM. (C) IFNg secretion by Thy1.1 T or CAR-T cells in 24-hr co-culture at
decreasing cell ratios with Thy1.2 BM (n = 5; mean ± SD; **p < 0.01). (D) FACS analysis assessment of Thy1.1 c-kit CAR-T cell-mediated depletion of c-kit+ Thy1.2 BM cells in
1:1 cell ratio co-culture at 24 hr. Percentge of total cell viability in the culture dishes, percentage of c-kit+ cells in BM population, and their mean fluorescence intensity (MFI) are
shown in each panel. (E) Summary results of FACS analyses of the same cytotoxicity co-culture as (D), but at different ratios of T cells to BM (n = 5; mean ± SD; **p < 0.01 and
*p < 0.05). (F) Photograph of colony formation assays following Thy1.1 c-kit CAR-T cell-mediated depletion of c-kit+ Thy1.2 BM cells in 1:1 cell ratio co-culture that was plated
at 24 hr and read at 10 days. (G) Colony formation numbers in the same experimental conditions and analysis as (F) but at different ratios of T cells to BM (n = 5; mean ± SD;
***p <0.001 and **p < 0.01).
www.moleculartherapy.org
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trafficking to BM and significantly delayed effect on the BM c-kit+
population.
CXCR4 is a chemokine receptor that regulates leukocyte trafficking
and in particular is important for trafficking to and adhesion within
BM.28,29 Though T cells do express low amounts of CXCR4, we
explored the forced higher expression of CXCR4 in c-kit CAR-T cells
by transduction with g-retrovirus encoding murine CXCR4 cDNA
(Figure 3C) as a means of inducing enhanced migration to and reten-
tion in BM. Administration of c-kit CAR-T cells with transduction-
mediated overexpression of CXCR4 (CXCR4+ c-kit CAR-T cells)
following CY pre-treatment of the mice significantly altered the
pattern of luciferase luminescence in the whole-body imaging studies,
such that the majority of signal switched from spleen to sites sugges-
tive of improved trafficking to BM (Figure 3D; Figure S3). This
conclusion was supported by specific FACS studies of BM outlined
next.
BM cells harvested from the Thy1.1+ c-kit CAR-T cell-injected mice
were subjected to FACS analysis in order to evaluate the expansion
and migration of the Thy 1.1+ c-kit CAR-T cells in a quantitative
manner, exploring both the effect of CY pre-treatment and the effect
A B C D
E F
Figure 3. Trafficking and Expansion of Thy1.1 c-kit CAR-T Cells in Thy1.2 Mice
(A) Timeline of Thy1.1 CAR-T cell production, in vivo administration, expansion, and trafficking. (B) In vivo whole-body luciferase luminescence imaging overlaid on X-ray
image at day 8 following injection of luciferase+ T (or CAR-T) cells with or without CY pre-treatment, where white arrow indicates spleen. Additional mice are shown in
Figure S3. (C) FACS analysis of CXCR4 and c-kit CAR on T cells transduced with c-kit CAR alone (upper panel) or co-transduced with CXCR4 (lower panel). (D) In vivowhole-
body luciferase luminescence imaging overlaid on X-ray image at day 8 following tail vein injection of luciferase+ CXCR4+ c-kit CAR-T cells into CY-pre-treated mice (right
image).White arrows show sites suggestive of BM activity. Additional mice are shown in Figure S3. (E) FACS detection in BMof c-kit CAR or CXCR4+ c-kit CAR-T cells without
or with CY pre-treatment as indicated at days 4 and 8 after CAR-T cell administration. (F) Time course of changes in percent (left panel) and actual cell numbers (right panel) of
c-kit CAR-T cells in BM using the same conditions as indicated in (E) (n = 5; mean ± SD; ***p <0.001 and *p < 0.05).
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of CXCR4 co-transduction during generation of the CAR-T cells.
Three conditions were compared: (1) injection of c-kit CAR-T cells
without CY pre-treatment, (2) injection of c-kit CAR-T cells with
CY pre-treatment, and (3) injection of CXCR4+ c-kit CAR-T cells
with CY pre-treatment. In the representative FACS dot plot analyses
shown in Figure 3E, the condition without forced expression of
CXCR4 and without CY pre-treatment (condition 1, upper row) re-
sulted in low levels of migration to BM; the condition without forced
expression of CXCR4 but with CY pre-treatment did increase the
number of c-kit CAR-T cells in BM (condition 2, middle row); and
the combination of forced expression of CXCR4 and CY pre-treat-
ment resulted in the highest level of entry of these CXCR4+ c-kit
CAR-T cells into BM (condition 3, bottom row). Naive mouse BM
without CY or CAR-T cell treatment is shown at the upper left side
of Figure 3E. The time course of each of the three conditions tested
over several experiments (n = 5) is shown in Figure 3F (left panel,
percentage of CAR-T cells in BM), where there is a >50-fold differ-
ence between condition 1 and condition 3 and slightly more than a
2-fold difference between condition 2 and condition 3. Actual
numbers of CAR-T cells in the BM (per 2 femurs) are also displayed
in Figure 3F (right panel). The apparent substantial increase of per-
centage of c-kit CAR-T cells in the BM at day 12 and later was in large
part due to a significant reduction of total BM cells, as shown below.
Based on these observations, all subsequent studies (unless noted)
were performed with T cells transduced to express both c-kit CAR
and CXCR4, andmouse recipients of these CXCR4+ c-kit CAR-T cells
were pre-treated 1 day before with CY at 125 mg/kg.
Depletion of BM Cells after In Vivo Injection of c-kit CAR-T Cells
We next explored the effect of CY conditioning alone or CY condi-
tioning plus CXCR4+ c-kit CAR-T cell treatment on PB counts (Fig-
ure 4A), BM cellularity (Figure 4B), BM colony formation (Figure 4C),
and the percent and absolute number of the BM KSL (c-kit+sca1
+Lineage) primitive stem cell population (Figures 4D and 4E). Since
these mice were not given any BM transplant, the administration of
CY conditioning plus CXCR4+ c-kit CAR-T induced anemia, throm-
bocytopenia, leukopenia, and absolute neutropenia (Figure 4A, red),
becoming so severe that most of the mice did not survive more than
5 weeks. Controls receiving only CY (125 mg/kg) without CAR-T
cells did not become anemic, thrombocytopenic, or neutropenic,
though the total leukocyte count (white blood cell [WBC]) did briefly
drop following endogenous T cell depletion by CY (Figure 4A, blue).
CY conditioning plus CXCR4 c-kit CAR-T resulted in less severe
and slowly progressing pancytopenia than CXCR4+ c-kit CAR-T
(Figure 4A, orange). Histological analyses of BM were performed
on day 12 using intact tibia of each mouse that was fixed, decalcified,
sectioned, and stained with H&E (Figure 4B). Sections of tibia BM ob-
tained from mice treated with CY+ CXCR4+ CAR-T was remarkably
hypo-cellular (Figure 4B, right panel), while BM from mice treated
with CY alone or CY+CXCR4 c-kit CAR-T was unchanged or in
milder hypoplasia compared to the naive BM (Figure 4B, the second
and third panels, respectively). As expected from the severe pancyto-
penia and hypocellular BM produced by treatment with CY plus
CXCR4+ c-kit CAR-T cells, the colony-forming capacity of BM in
those mice was severely depleted relative to either naive or CY
only-treated mice (Figure 4C).
The same BM samples were assessed for specific depletion of c-kit+
and KSL cells (Figures 4D and 4E), total BM cells (Figure 4E), and
those KSL cells that were also CD34CD135 (phenotype of long-
term repopulating [LT] HSCs) (Figure 4E). The CY only-mediated
depletion of T cells resulted in a transient modest decrease in total
BM cells at day 4 with recovery thereafter, but no effect on absolute
counts of c-kit+, KSL, or LT-HSC populations in the BM (Figure 4E).
In the CY+CXCR4+ c-kit CAR-T condition, by day 8 or beyond there
was a several log decrease in absolute count of c-kit+ cells (Figure 4E,
top right panel), absolute count of KSL cells (Figure 4E, bottom left
panel), and absolute count of LT-HSCs (Figure 4E, bottom right
panel) in BM, with the earliest and most severe depletion observed
in the LT-HSC population. Even the total BM nucleated cell count
was greatly decreased by day 12 (Figure 4E, top left panel). When
we performed the experiment using CY+CXCR4 c-kit CAR-T,
LT-HSC depletion did occur but was substantially delayed in both
time of onset and amount of this depletion (Figure 4E, orange).
Also of note is that these data from all the sections of Figure 4 again
show that CY treatment at 125 mg/kg does not itself cause either PB
cytopenia (except for the transient effect on T cells) or depletion of
BM HSC populations. Finally, as shown in Figure S2A (bottom
row), CY treatment at a dose of 125 mg/kg was both necessary and
sufficient pre-treatment to achieve the goal of CXCR4+ c-kit
CAR-T cell-mediated depletion of the KSL population in BM.
Furthermore, the importance of CY pre-treatment to achieve the
CXCR4+ c-kit CAR-T cell-mediated depletion of KSL from the BM
was demonstrated by the studies shown in Figure S2B, where
increasing doses or 3 consecutive days of administrations of high
doses of CXCR4+ c-kit CAR-T cells without CY pre-treatment only
modestly increased the percentage of these CAR-T cells in the BM
at day 8 (Figure S2B, upper panel), and they did not deplete BM
Figure 4. In Vivo Depletion of BM Cells after CY Only or after CY + CXCR4+ c-kit CAR-T Cell Treatment
(A) Time course of PB hemoglobin (Hgb), platelets (Plt), total leukocyte (WBC), and absolute neutrophil (Neut) count following CY alone (blue), CY + CXCR4 c-kit CAR-T
(orange), or CY + CXCR4+ c-kit CAR-T cell (red) compared with the naive (purple) (n = 5; mean ± SD; ***p < 0.001, **p < 0.01, and *p < 0.05). (B) Photomicrographs of H&E-
stained tibia sections from naive mouse or mice following CY only, CY + CXCR4 c-kit CAR-T, or CY + CXCR4+ c-kit CAR-T cell injection. (C) Photographs of in vitro colony
formation assay of BM cells from naive mice or mice on day 12 following CY only, CY +CXCR4 c-kit CAR-T, or CY +CXCR4+ c-kit CAR-T cell injection. Numbers of colonies
per plate are shown in the graph (n = 5; mean ± SD; ***p < 0.001; NS, not significant). (D) FACS analysis of BM obtained from naive mice or from mice at days 4 and 8 after
treatment with CY only, CY + CXCR4 c-kit CAR-T, or CY + CXCR4+ c-kit CAR-T cells, where boxes show percentage of KSL (c-kit+sca1+Lineage) cells. (E) Time course of
the same FACS analyses of mice as indicated in (D), but calculating and plotting absolute number of BM, c-kit+, KSL, or LT-HSC cells per 2 femurs per mouse (n = 3 [5 mice/
experiment; 15 mice total]; mean ± SD; ***p < 0.001, **p < 0.01, and *p < 0.05).
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KSL cells (Figure S2B, lower panel). In fact, at highest doses of
CXCR4+ c-kit CAR-T cells without CY pre-treatment, there was an
unexplained increase in KSL cells.
BM Transplantation for Mice Treated with c-kit CAR-T Cells
Having confirmed that CY conditioning plus CXCR4+ c-kit CAR-T
cell treatment is highly effective in depleting BMHSCs, we next deter-
mined procedures that would deplete the CXCR4+ c-kit CAR-T cells
sufficiently to allow subsequent engraftment of donor BM. Although
in the future it should be possible to add suicide elements to the
CAR-T cell construction to allow elimination of these cells once BM
HSC had been sufficiently depleted, for our current mouse model
system we were able to use specific anti-Thy1.1 antibodies to achieve
effective in vivo depletion of the congenic Thy1.1+ CXCR4+ c-kit
CAR-T cells from Thy1.2-recipient mice. As indicated in the timeline
shown inFigure 5A, byusing congenicThy1.1+CD45.2+CXCR4+ c-kit
CAR-T cells to treat Thy1.2+ CD45.2+ C57BL/6J mice, and using con-
genic Thy1.2+ CD45.1+ BM as donor cells, it was possible to use anti-
Thy1.1 antibody to deplete theThy1.1+CD45.2+CXCR4+ c-kit CAR-T
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Figure 5. CY Plus Congenic Thy1.1+ CD45.2+ CXCR4+ c-kit CAR-T Cell Facilitated Engraftment of Congenic Donor Thy1.2+ CD45.1+ BM into Thy1.2+ CD45.2+
C57BL/6J Mice following the Depletion of CAR-T Cells with Anti-Thy1.1 Antibody
(A) Timeline of c-kit CAR-T cell production and in vivo injection followed by Thy1.1 antibody depletion of c-kit CAR-T cells, transplantation of donor BM, and subsequent
evaluation of donor engraftment. (B) FACS analysis of congenic Thy1.1+ CD45.2+ CXCR4+ c-kit CAR-T cells in recipient BM at day 8 comparing before and 24 hr after (day 9)
i.p. injection of anti-Thy1.1 antibody (upper versus lower panels). (C) Percentage of all LT-HSCs in recipient BM that are donor phenotype by FACS analysis at 12 weeks after
transplant without conditioning, with CY alone, or after CY plus c-kit CAR-T cell conditioning and Thy1.1 antibody depletion of the c-kit CAR-T cells (n = 5; mean ± SD;
***p < 0.001). (D) Time course of percentage of B cell, T cell, and granulocyte lineages in the PB that are donor phenotype by FACS analysis at 0, 4, 8, and 12weeks and 6 and
9 months after transplant mediated by CY plus c-kit CAR-T cell conditioning and Thy1.1 antibody depletion of the c-kit CAR-T cells (n = 3 [5 mice/experiment; 15 mice total];
mean ± SD; ***p < 0.001 and **p < 0.01).
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Thy1.2+CD45.1+ donor BMengraftment in theThy1.2+CD45.2+ host.
In this scheme, production of Thy1.1+ CD45.2+ CXCR4+ c-kit CAR-T
cells, CY pre-treatment (125 mg/kg), and injection of these c-kit
CAR-T cells were performed per the methods and timetable in exper-
iments in Figures 3 and 4, except that at day 11 mice were injected i.p.
with anti-Thy1.1 antibody and transplanted with donor BM on day 12
(Figure 5A). When discussing donor chimerism assessed post-trans-
plant, the day of BM transplant is re-set as day 0/Week 0. We demon-
strate that Thy1.1+ CD45.2+ CXCR4+ c-kit CAR-T cells were
completely depleted from the Thy1.2+ CD45.2+ C57BL/6J recipient
mice at 24 hr after a single i.p. injection with 500 mg anti-Thy1.1 anti-
body (Figure 5B, compare top and bottom panels). Also following
anti-Thy1.1 antibody treatment, there were no residual c-kit CAR-T
cells detected in PB, spleen, thymus, and lymph nodes as assessed by
FACS analysis (Figure S4). At 24 hr after Thy1.1 antibody treatment,
recipient mice were injected by tail vein with 3  106 BM cells from
Thy1.2+CD45.1+ donor mice that had been prepared for donation by
5-fluorouracil (150 mg/kg, 4 days before harvest).
As shown in Figures 5C and 5D, congenic donor BM was trans-
planted into recipient mice that received neither CY nor CXCR4+
c-kit CAR-T cells (no conditioning); into recipient mice receiving
CY, but not CXCR4+ c-kit CAR-T cells (CY alone); or into recipient
mice that received CY pre-treatment plus CXCR4+ c-kit CAR-T cells
and subsequent depletion with Thy1.1 antibody (CY + CAR-T +
Thy1.1 Ab). PB was sampled at 4-week intervals. The mice from
one of the three experiments (5 mice per condition) were sacrificed
at 12 weeks to assess BM engraftment by determining the percentage
of LT-HSCs that were donor phenotype (CD45.1+ CD45.2), while
mice from the other two experiments were kept alive so that PB could
continue to be sampled for a much longer period of time. At 12 weeks,
there was essentially no donor engraftment of LT-HSCs in mice
receiving no conditioning or with CY alone, but engraftment of the
donor LT-HSC phenotype in mice receiving the CY + CAR-T +
Thy1.1 Ab-conditioning regimen ranged from 9.9% to 36.3% with a
mean of 26.9% (Figure 5C). PB was sampled at 4-week intervals
from all mice in the three experiments (5 mice per experiment per
condition). There was no detectable engraftment of donor lineages
in the PB of transplanted mice receiving either no conditioning or
CY alone treatment (data not shown). In Figure 5D is shown the
time course of appearance of donor cells in 3 lineages of the PB as-
sessed up to 9 months in all 15 transplanted recipient mice who
had received the CY + CAR-T + Thy1.1 Ab-conditioning regimen.
Donor chimerism for granulocytes plateaued at 8 weeks, where at 8
and 12 weeks chimerism averaged 22.9% (range 11%–36%). As
would be expected, there was a lag in PB donor B and T cell chime-
rism, but by 12 weeks it was similar to that of PB granulocytes. Resid-
ual CAR-T cells were not detected in the PB at any time points after
transplantation by FACS analyses.
Treatment of CGDMice Using c-kit CAR-T Cell Conditioning and
BM Transplantation
We next applied c-kit CAR-T cell conditioning to wild-type donor
mouse BM transplant of the X-linked chronic granulomatous disease
(CGD) mouse, as shown in Figure 6A. This CGDmouse has a disrup-
tive insertion in the gene encoding the gp91-phox subunit of the
phagocyte NADPH oxidase, such that granulocytes and monocytes
fail to produce microbicidal reactive oxygen species (ROS) when
stimulated.30 The functional defect in ROS generation can be
measured in PB granulocytes using the dihydrorhodamine 123
(DHR) flow cytometry assay,31 as shown in Figure 6B, where phorbol
12-myristate 13-acetate (PMA) stimulation of normal results in ROS
mediated conversion of DHR to highly fluorescent rhodamine in
>98% of normal wild-type mouse granulocytes (Figure 6B, middle
panel), which is lacking in stimulated CGD mouse granulocytes (Fig-
ure 6B, right panel). In the CGD mice, the BM KSL population was
almost the same as normal C57BL/6J mice (Figure 6C, left panel),
and this population was completely depleted after the treatment
with CY + CAR-T and BM displayed severe aplasia, just as we
observed in the normal C57BL/6J mice (Figure 6C, right panel). After
c-kit CAR-T cell mediated transplantation of BM from naive mice
(Thy1.2+CD45.1+) to CGD mice (Thy1.2+CD45.2+) following the
scheme in Figure 6A, there was now normal production of ROS
from the engrafted CD45.1+ donor granulocytes (Figure 6D, middle
panel). In the mouse analyzed in this panel, 35% of circulating gran-
ulocytes were DHR positive. The time course shown for reconstitu-
tion of oxidase normal granulocytes in the PB of 5 CGD mice
transplanted with normal wild-type BM following c-kit CAR-T cell
conditioning is shown in Figure 6D (right panel). At week 12 the
average percentage of oxidase-normal granulocytes in the PB of these
transplanted CGD mice was 28% (range 18%–36%).
DISCUSSION
In the current study, we have established a mouse c-kit CAR-T cell
BM-conditioning method to achieve substantial engraftment of con-
genic donor BM. In our in vitro and in vivo studies, we specifically
show that (1) mouse c-kit CAR-T cells in vitro specifically bind and
kill c-kit+ cells (including both cell lines and BM cells), and this
killing is associated with high-level IFNg release by the c-kit
CAR-T cells; (2) mouse c-kit CAR-T cells require transduction-
mediated overexpression of CXCR4 to achieve adequate migration
into the BM; (3) pre-treatment of mice with low-dose CY
(125 mg/kg) 1 day prior to the administration of CXCR4+ c-kit
CAR-T cells is both necessary and sufficient to achieve the required
expansion of c-kit CAR-T cells that is needed to significantly deplete
LT-HSCs or KSL cells from recipient BM; (4) this expansion and
increased migration into the BM by the CXCR4+ c-kit CAR-T cells
resulted in persistent BM aplasia and eventual death from aplastic
anemia; and, (5) following the achievement of BM depletion over
10 days, elimination of the CXCR4+ c-kit CAR-T cells can be
accomplished using Thy1.1 antibody to allow engraftment donor
BM. These maneuvers, such as the initial CY administration, injec-
tion of CXCR4+ c-kit CAR-T cells, followed by elimination of the
CXCR4+ c-kit CAR-T cells at a time of maximum recipient HSC
depletion, allow >20% long-term congenic BM multilineage engraft-
ment. An important aspect of the use of a CXCR4+ c-kit CAR-T cell
approach to BM conditioning is the avoidance of ionizing radiation
or strong alkylating agents such as busulfan, which may also
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Figure 6. Treatment of gp91-phox-Deficient CGD Mice
with Normal Wild-Type BM Transplantation Using
Sequential CY + CAR-T + Thy1.1 Ab Conditioning
(A) Timeline of c-kit CAR-T cell production and in vivo injection
into CGD mice followed by Thy1.1 antibody depletion of c-kit
CAR-T cells, transplantation of donor normal wild-type BM, and
subsequent evaluation of donor engraftment and assessment
of the appearance of DHR+ oxidase normal granulocyte in the
PB of transplanted CGD mice. (B) DHR flow cytometry analysis
of ROS production by PB granulocytes without or with PMA
stimulation from a normal wild-type mouse (middle and left
panels) or CGD mouse (right panel) (gated on granulocyte
Gr1+Mac1+ population). (C) FACS analysis of BM obtained from
untreated and CY + CAR-T-treated CGD mice at day 8, where
boxes show percentage of KSL (c-kit+sca1+Lineage) cells.
(D) Normal wild-type donor PB granulocyte chimerism (CD45.1)
in c-kit CAR-T cell-conditioned CGD mice (CD45.2) was
assessed together with measurement of DHR oxidase activity
(PMA stimulation) before transplantation (left panel) and
12 weeks after transplantation of normal wild-type BM into
CGD mice conditioned with c-kit CAR-T cells (right panel).
Time course of percentage of DHR+ cells (in granulocyte
fraction) is shown in right panel at 0, 4, 8, and 12 weeks after
transplantation (n = 5; mean ± SD; ***p < 0.001).
www.moleculartherapy.org
Molecular Therapy Vol. 26 No 5 May 2018 1191
damage or inflame both BM and thymus stroma, and this may pro-
vide a more favorable environment for BM transplant and restora-
tion of lymphoid immunity.32
The g-retrovirus c-kit CAR construct, which we used in this study to
produce mouse c-kit CAR-T cells, showed high efficacy of transduc-
tion, and the resultant c-kit CAR-T cells demonstrated high speci-
ficity and robust cytotoxicity, activity of which depends on the extra-
cellular single-chain variable fragment (scFv) and the intracellular
signaling domain. Many studies have examined the effect of various
arrangements of extracellular scFv domains for CAR-T cells, assess-
ing the effect on functional activity of the orientation of VL and VH
and the types of linker domain between these variable regions in
the constructs.25,33 To date, there are no strategies that can predict
the most suitable structure for each individual CAR construct without
empiric assessment. To achieve optimum design of our final c-kit
CAR, we produced c-kit CAR-T cells with multiple combinations
of scFv (Figure S1), and we found that only one of the combinations
we constructed and assessed could efficiently generate highly func-
tional CAR-T cells targeting c-kit+ cells for efficient killing.
Given the highly effective killing of c-kit+ cell lines or primary BM
HSCs in culture by our c-kit CAR-T cells, we were disappointed to
find that simply injecting even very large numbers of these cells
into mice without other maneuvers resulted in no depletion of BM
HSCs in vivo. We did not present in the Results our initial alternative
attempts to improve the effect of the c-kit CAR-T cells that included
pre-treatment with low-dose busulfan and/or low-dose radiation,
neither of which achieved any synergy with the c-kit CAR-T cells
in killing BM HSCs in vivo. We also failed to observe any HSC deple-
tion when we tried using plerixafor (CXCR4 antagonist) to mobilize
HSCs into the PB, hoping that would increase access of the c-kit CAR-
T cells to HSCs. The next strategy we tried was administration of CY,
based on the observation from human clinical trials using CAR-T
cells,20,21 where pre-treatment with a T cell-depleting agent such as
CY significantly enhanced efficacy in part by stimulating expansion
in vivo. In that setting CY might also be working to eliminate endog-
enous regulatory T cells.34 The use of CY in our mouse model
achieved significant expansion of the c-kit CAR-T cells in vivo,
including increased numbers in the BM, and it did result in a slow
pace of depletion of BM cells, but still it was not itself sufficient to
observe the rapid complete elimination of LT-HSC phenotype cells.
We previously demonstrated that transduction-forced overexpres-
sion of CXCR4 in HSCs can increase engraftment in BM, even though
HSCs naturally express endogenous CXCR4.28 Similarly, T cells ex-
press some endogenous CXCR4, but we postulated that transduc-
tion-forced higher expression of CXCR4 on the c-kit CAR-T cells
might not only increase the efficiency and speed of trafficking to
BM but also might increase retention within the BM as well as
bringing them into more intimate contact with HSCs. This final
maneuver (CXCR4 overexpression) together with low-dose CY
pre-treatment achieved the required goal of highly efficient rapid
clearance by day 8 of c-kit+ cells from the BM, particularly those
with LT-HSC markers.
Regarding the choice of CY dosage, we were guided by previous
studies of the use of CAR-T cells for tumor killing in mouse models
where CY at 100–250 mg/kg had been explored and shown to be
effective.26,27 To the best of our knowledge, it had not been possible
to observe efficient tumor targeting-effects from second-generation
CAR-T cells in immunocompetent mice without the use of CY or
other lymphocyte depletion strategies. The function and effect of
low-dose CY in vivo, which mainly relies on its metabolites (particu-
larly 4-hydroxy-cyclophosphamide),35 have been seen to depend on
both overall suppression of lymphocytes and effects on regulatory
T cells.36 Moreover, higher doses of CY than we used in our study
or the combination of other chemotherapies were necessary to induce
HSC depletion in BM and to allow donor graft to be engrafted in the
immunocompetent mice; 400 mg/kg CY,37 40–70 mg/kg busulfan
plus 200 mg/kg CY,38–40 or 300 mg/kg fludarabine and 150 mg/kg
CY41 were used as BM-conditioning protocols in previous studies.
In our study, we selected 125 mg/kg i.p., which was the minimal
dose we found empirically to be required for CAR-T cell expansion
and to achieve the desired effect of the c-kit CAR-T cells on BM
HSCs, but which did not itself without c-kit CAR-T cells have any ef-
fect on BM cellularity, BM colony formation, or PB cell counts. Not
shown is that we measured and confirmed that regulatory T cells
were depleted by low-dose CY (125 mg/kg), an effect that might be
in part responsible for the expansion, migration into BM, and
enhanced killing of BM HSCs by CXCR4+ c-kit CAR-T cells.
CXCR4 is the chemokine receptor for C-X-C chemokine ligand
(CXCL) 12, known as stromal cell-derived factor (SDF)-1a, which
is broadly expressed in the BM HSC niche.42 Expression of CXCR4
on the cell surface works both as a homing signal to BM and as a
retention signal for cells in the BM. HSCs naturally express endoge-
nous CXCR4,42 but forced additional expression by transduction of
CXCR4 enhances the engraftment of HSCs.28 Moreover, gain-of-
function mutations of CXCR4 are a cause ofWHIM syndrome, which
results in a panleukocytopenia in the PB but hyperplasia in the BM,
including retention of neutrophils in the BM to their point of senes-
cence, suggesting that this stronger binding with WHIM mutant
C-terminal-truncated CXCR4 prevents the release of neutrophils
into the PB from the BM.29 From this, it is possible to postulate
that transduction-mediated increased CXCR4 expression in the
c-kit CAR-T cells not only enhances migration but also increases
retention in the BM. A previous study in human HSCs indicated
that CD34+ cells express both CXCR4 and CXCR4 ligand
(CXCL12),43 raising the possibility that the co-expression of
CXCR4 on the CAR-T cells might be serving as a bi-functional bind-
ing element with the c-kit-binding element in targeting mouse HSC.
However, cell surface expression of CXCL12 was not detected in
whole BM and the KSL population in our mouse study (Figure S5).
Because CXCL12 is particularly highly expressed in the BM niche
on stromal cells,42 overexpression of CXCR4 could reduce off-target
effects of c-kit CAR-T cells. However, there is expression of c-kit by
tissues outside of the BM, including germ cells, melanocytes, Cajal
cells of the gastrointestinal tract, and subsets of cerebellar neurons
in addition to BM HSCs/progenitor cells.44 Despite this, we did not
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grossly observe off-target effects such as hair graying from any effect
onmelanocytes, which was reportedly observed after anti-mouse c-kit
antibody (ACK2) administration.45
As noted, the transduction-mediated overexpression of CXCR4 in the
c-kit CAR-T cells had a major impact on the pace and extent of
clearance of HSCs from the BM. This successful use of a chemokine
receptor to direct and possibly hold CAR-T cells to a desired anatomic
location, where their action on a target cell typemay be amplified, may
be one of themost important findings of our studies in that it may pro-
vide a general principle that could be applied to other applications of
CAR-T cells. Specific to CXCR4-mediated targeting, it is possible that
its use for CAR-T cells directed at antigens to treat myeloid leukemia
might augment effectiveness in the way that its use in our study
augmented the effectiveness of c-kit CAR-T cell killing of HSCs in
the BM. Solid tumors or myeloid leukemia has proven to be a partic-
ularly difficult target for CAR-T cell treatments, likely for a variety of
reasons,46 but it is possible that influencing trafficking to and/or
tethering in a solid tumor by increased expression of a migration or
tethering receptor might be a useful element to explore.47
In conclusion, our findings in this mouse study provide a first proof
of concept that CXCR4+ c-kit CAR-T cells can be used to achieve BM
HSC clearance sufficient to result in substantial (>20%) levels of long-
term stable multilineage engraftment of congenic BM in immuno-
competent mice. Despite this accomplishment, more work is required
to optimize this approach to achieve higher levels of engraftment in
both the congenic setting and in a partial major histocompatibility
complex (MHC) mismatch setting that we did not explore in this
study. In addition, there are applicability and safety issues that
must be addressed before being able to consider this for a human
treatment setting. For example, in the congenic mouse models we
used for this study, anti-Thy1.1 antibody proved highly effective at
completely eliminating the Thy1.1+CXCR4+ c-kit CAR-T cells in
the Thy1.2+ recipient to allow engraftment of congenic BM, but, in
the future, we will need to explore alternate strategies more applicable
to the human setting to eliminate the CXCR4+ c-kit CAR-T cells such
as the built-in suicide gene system,48 mRNA-electroporated CAR-T
cells, T cell ablation with alemtuzumab, or CAR-T cell ablation
with rituximab by using CD20-coexpressing CAR-T cells.49 Other
maneuvers that we will explore that might further enhance the effi-
ciency of the c-kit CAR-T cells might include use of C-terminal-trun-
cated versions of CXCR4 that imitate WHIM syndrome mutations
that greatly enhance the activity of this receptor by interfering with
internalization and downregulation.
MATERIALS AND METHODS
Construction of g-Retrovirus Encoding c-kit CAR and
Transduction of Mouse T Cells
We determined the cDNA sequence of the ACK2 monoclonal anti-
mouse c-kit antibody by extracting mRNA from the hybridoma cell
line.50 Reverse-transcribed cDNA was subject to rapid amplification
of cDNA ends (RACE) PCR (SMARTer RACE 50/30 Kit, Clontech
Laboratories, Mountain View, CA, USA) using the universal primer
for variable regions of immunoglobulin heavy and light chains (VH
and VL).
51 The PCR products generated were inserted into a cloning
vector (Zero Blunt TOPO PCR cloning kit, Invitrogen, Carlsbad, CA,
USA), and DNA sequence was determined using Sanger method by
Macrogen USA (Rockville, MD, USA). From the obtained sequence
information, variable regions in both chains were determined using
an online database program (IMGT/V-QUEST program, version
3.4.7). Double-stranded DNA including these two regions (VH and
VL) was connected with either of two linker sequences previously em-
ployed in CAR construction (the 218 linker33 or the (G4S)3 linker
25)
and followed by the downstream mouse CD8, CD28, and CD3z
cDNA52 that had been synthesized in vitro (Integrated DNATechnol-
ogies, Coralville, IA, USA); and it was cloned into retroviral vector
backbone containing the MSGV promotor.52
This retroviral vector plasmid (pMSGV c-kit CAR) was transfected
into the Platinum-E, a 293T-based retroviral packaging cell line with
ecotropic envelope (plat-E) (Cell Biolabs, San Diego, CA, USA).
Transfection of confluent plat-E was performed in 10-cm dish using
12 mg pMSGV c-kit CAR plasmid along with transfection reagent
(15 mL X-treamGENEHPDNA Transfection Reagent, Roche Applied
Science, Mannheim, Germany), and g-retrovirus was harvested 48
and 72 hr later. As a control, previously described g-retrovirus-encod-
ing mouse VEGFR-2 CAR24 was prepared in the same way.
As donors of T cells, C57BL/6J mice congenic for Thy1.1 (wild-type
C57BL/6J strain are Thy1.2) were purchased (B6.PL-Thy1a/CyJ,
JAX406, The Jackson Laboratory, Bar Harbor, ME, USA). Spleens
were harvested from this strain (8–12 weeks old), and T cells were
isolated from them using negative selection technique (Dynabeads
Untouched Mouse T Cells, Invitrogen), followed by in vitro culture
with CD3/28 antibody stimulation (Dynabeads Mouse T-Activator
CD3/CD28, Gibco, Gaithersburg, MD, USA). For the purpose of
transduction, g-retrovirus for c-kit CAR (or VEGFR-2 CAR as the
control) was adhered to the fibronectin-coated culture plate
(RetroNectin, Takara Bio, Shiga, Japan) (centrifuging at 2,500 rpm
for 2 hr); then, stimulated and expanded T cells were infected with
g-retrovirus on the plate. CAR expression was evaluated by FACS
(FACS Canto, BD Biosciences, San Jose, CA, USA) at 24–48 hr after
transduction with the staining of mouse anti-Fab antibody conju-
gated with biotin (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) and imaged with streptavidin PE (BD Biosciences).
Recombinant mouse c-kit protein conjugated with mouse Fc or
mouse VEGFR-2 protein conjugated with human Fc (c-kit-Fc and
VEGFR-2-Fc obtained from R&D Systems, Minneapolis, MD,
USA) along with anti-mouse/human Fc-APC secondary antibodies
(Jackson ImmunoResearch) was used to evaluate the specific binding
of CAR-T cells to the target proteins. For all FACS studies noted here
or below, cells were stained with Zombie NIR Fixable Viability Kit
(BioLegend, San Diego, CA, USA) to allow gating to distinguish alive
and dead cells.
We also constructed a g-retrovirus vector plasmid encoding cDNA
for mouse CXCR4 (plasmid encoding murine CXCR4 from OriGene,
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Rockville, MD, USA), and we prepared ecotropic enveloped vector as
outline above using plat-E. For those experiments requiring c-kit
CAR-T cells also expressing excess CXCR4, T cells were co-trans-
duced with both the c-kit CAR vector and the CXCR4 vector in the
same culture. Surface expression of CXCR4 was detected with anti-
mouse CXCR4 antibody (BD Biosciences).
In Vitro Co-culture Assay
Mouse cell lines with strong expression of c-kit were prepared to use
as targets of c-kit CAR-T cells. NIH 3T3 (originally sourced from
American Type Culture Collection, Manassas, VA, USA) and the
mouse B cell leukemia cell line that expressed CD19 (E2a-PBX)53
were each transduced for three times with a third-generation
lentivirus54 into which we substituted mouse c-kit cDNA sequence
(OriGene). Cell surface c-kit expression was confirmed by FACS after
staining with anti-mouse c-kit antibody (BD Biosciences). To
enhance visibility under the fluorescent microscope, the NIH 3T3
cells in some experiments were co-transduced with the same lentivec-
tor encoding GFP.
For the in vitro co-culture assay of target cell killing by CAR-T cells,
the various c-kit-expressing and control target cell lines (2.5  105
cells) and mouse unfractionated BM (harvested from wild-type
C57BL/6J with CD45.2+Thy1.2+; JAX664 purchased from The
Jackson Laboratory) were mixed with CAR-T cells and controls
(4.0  103–2.5  105 cells from CD45.2+Thy1.1+ mice) in the
24-well plate for 24 hr. Harvested supernatant was subjected to ELISA
assay of mouse IFNg (Quantikine ELISA, R&D Systems), and
cultured cells were analyzed with FACS using anti-mouse CD19,
CD3, and c-kit antibodies (BD Biosciences). NIH 3T3 cells (marked
with GFP) were examined and photographed by fluorescent micro-
scopy analyses (EVOS FL Cell Imaging System, Life Technologies,
Carlsbad, CA, USA) to determine the viability after one-time gentle
wash following 24-hr co-culture.
BM cells (4 104 cells) co-cultured with c-kit CAR-T cells were trans-
ferred to nitrocellulose medium with complete cytokines in a 6-cm
dish (Methocult medium, STEMCELL Technologies, Vancouver,
Canada) after 24-hr incubation in the normal RPMI-1640 medium
(Life Technologies). Colony number was counted visually or photo-
graphed on day 10 using an invertedmicroscope (Eclipse Ti-U, Nikon
Instruments, Melville, NY, USA), with colony type enumerated
according to each type of colony (BFU-E, CFU-M, -G, -MG, and
-GEMM), though for most studies the total number of colonies was
compared among each condition.
In Vivo Injection of CAR-T Cells and Evaluation of Their Function
CAR-T cells generated from the abovementioned donor mice spleen
T cells (C57BL/6J with CD45.2+Thy1.1+) or from luciferase-trans-
genic mice (B6;FVB-Ptprca Tg(CAG-luc,-GFP)L2G85Chco Thy1a/J;
JAX25854 purchased from the Jackson Laboratory) were harvested
24 hr after g-retrovirus transduction and re-suspended in the infu-
sion buffer (PBS with 0.1% BSA) (Sigma-Aldrich, St. Louis, MO,
USA) at the concentration of 5  106 cells/100 mL. Recipient mice
(C57BL/6J with CD45.2+Thy1.2+) without or with administration
of low-dose CY i.p. (125 mg/kg) (Sigma-Aldrich) were subjected to
CAR-T cell injection intravenously via tail vein 24 hr after CY treat-
ment. For some experiments, different dosing of CY (62.5 mg/kg,
125 mg/kg, and 250 mg/kg) was explored.
Expansion and trafficking of injected CAR-T cells (generated from
luciferase transgenic mice described above) were analyzed by an
in vivo imaging system (In-Vivo Xtreme, Bruker, Billerica, MA,
USA). Luciferase-transgenic mice c-kit CAR-T cells (without or
with co-transduction of CXCR4) were injected into recipient mice,
and 7 days after injection they were treated with luciferin i.p. injection
(3 mg) (VivoGlo Luciferin, Promega, Madison, WI, USA), and
emitted whole-body fluorescence was detected by in vivo imaging.
The pictures were overlaid onto the X-ray images of each mouse to
determine the anatomic correlations.
CAR-T cell presence and effects in vivowere assessed by PB count and
BM harvest count, as well as FACS assessment of lineages. BM pop-
ulations were also analyzed by colony formation assay and histology.
PB cell counts were determined with automated hemocytometer
(Hemavet 950, Drew Scientific Group, Miami Lakes, FL, USA), and
BM cell numbers per two femurs were calculated in each mouse using
trypan blue staining to assess live cells (Lonza, Walkersville, MD,
USA). For FACS analysis, cells were stained with anti-mouse
Thy1.1, Thy1.2, CD3, CD19, c-kit, sca1, CD135, and CD34 antibodies
along with the lineage mix cocktail (BD Biosciences), and they were
analyzed with FACS Canto or Fortessa (BD Biosciences). For colony
assay, BM cells (4  104 cells) harvested from the treated mice were
transferred to Methocult nitrocellulose medium with complete
cytokines, and colony number was counted on day 10. In some exper-
iments, H&E-stained slides of tibia were prepared by American
Histolabs (Gaithersburg, MD, USA) and analyzed to determine the
cellularity of BM using the microscopy (Axio ImagerZ1, Carl Zeiss
Vision, San Diego, CA, USA).
BM Transplant after CAR-T Cell Injection and Chimerism
Evaluation
Recipient mice (C57BL/6J with CD45.2+Thy1.2+) injected with
CXCR4+ c-kit CAR-T cells (derived from C57BL/6J with CD45.2+
Thy1.1+ mice) after low-dose treatment of CY (125 mg/kg i.p.)
were injected with 500 mg anti-mouse Thy1.1 antibody by i.p. admin-
istration (InVivomAb anti-mouse Thy1.1, clone 19E12, Bio X Cell,
West Lebanon, NH, USA) on day 11 in order to deplete CAR-T cells.
These recipient mice were then transplanted with BM cells harvested
from C57BL/6J with CD45.1+Thy1.2+ donor mice (B6.SJL-Ptprca
Pepcb/BoyJ; JAX2014 purchased from The Jackson Laboratory). The
BM donor mice were pre-treated with 150 mg/kg 5-fluorouracil
(Sigma-Aldrich) 4 days before BM harvest to deplete mature cells,55
and 3  106 donor BM cells per recipient mouse were intravenously
transplanted by tail vein.
Chimerism between CD45.1 (donor) and CD45.2 (recipient) cells was
determined at 4, 8, and 12 weeks and 6 and 9 months in the PB, and
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somemice were sacrificed at 12 weeks to harvest and examine lineages
in the BM, including KSL or c-kit+ HSCs. Anti-mouse CD45.1 and
CD45.2 antibodies were used along with T cell (CD3+), B cell
(CD19+), granulocyte (Gr-1+Mac1+), and long-term HSC (LT-HSC;
Lineagec-kit+sca1+CD135CD34) markers to perform FACS
analyses for the chimerism assessment (BD Biosciences).
For CGD mouse treatment experiments, gp91-phox-deficient mice
(B6.129S-Cybbtm1Din/J; JAX2365 purchased from the Jackson Labora-
tory) were used as recipients (Thy1.2+CD45.2+), and they were trans-
planted with BM from C57BL/6J CD45.1+Thy1.2+ donor normal
wild-type mice using the same conditioning protocol that sequentially
employs CY + CAR-T + Thy1.1 Ab. For the post-transplant analysis
of ROS, production by PB granulocytes was measured using the DHR
assay.31 More specifically, mouse PB was subjected to erythrocyte lysis
and loading of DHR (LifeTechnologies) followed by stimulation with
PMA (final 10 ng/mL) for 15 min. ROS production by DHR analysis
was detected in the granulocyte (Gr-1+Mac1+) fraction.
All the animal studies were in accordance with NIH Guide for the
Care and Use of Laboratory Animals, and the specific experiments
and mouse strains were approved by the National Institute of Allergy
and Infectious Disease Animal Care and Use Committee (NIAID
ACUC) under animal use protocol LHD-3E (now LCIM-1E).
Statistical Analyses
Experiments were repeated at least 3–5 times independently, though
some transplant studies where specifically indicted were a single
experiment with 5 mice. Values were described as the mean ± SDs.
Data were compared with Student’s t test or ANOVA, and statistical
analyses were performed using GraphPad Prism (version 7.0c,
GraphPad, La Jolla, CA). The alpha level of all tests or the p value
was set at 0.05.
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Effect of linker choice ( “218” versus “(G4S)3” ) and the VH and VL order on CAR expression
Schematics of four extracellular domain constructs are shown above each FACS dot plot (side 
scatter by Fab detection) of T cells transduced with versions of c-kit CAR containing the indicated 
domains.

































































































































































CY 62.5 mg/kg 125 mg/kg 250 mg/kg
Day8 BM
CY+CAR-T (CXCR4+)
CY 62.5 mg/kg 125 mg/kg 250 mg/kg
Gated to live Lineage− population
Gated to live Lineage− population
CAR-T
CAR-T
Dose effect of CY treatment on BM and dose response of CXCR4+ c-kit CAR-T cell administration on BM
(A) FACS analyses of CY dose response effect on BM KSL population (upper row), on trafficking of CXCR4+ c-kit CAR-T 
cells to BM (middle row), and on the CXCR4+ c-kit CAR-T cells mediated depletion of BM KSL population (lower panel). 
(B) FACS analyses of dose response of CXCR4+ c-kit CAR-T cell administration to mice without CY pre-treatment on 






In vivo whole body luciferase luminescence imaging
In vivo whole body luciferase luminescence imaging overlaid on X-ray imaging at Day 8 following tail vein injection of 
transgenic luciferase+ Thy1.1 untransduced T cells (naïve), CXCR4- c-kit CAR-T cells without CY pre-treatment (CAR-T 
only), CXCR4- c-kit CAR-T cells with CY pre-treatment (CY+CAR-T; CXCR4-), or CXCR4+ c-kit CAR-T cells with CY 
pre-treatment (CY+CAR-T; CXCR4+).
Figure S4
FACS analysis of residual c-kit CAR-T cells in other organs after anti-Thy1.1 antibody injection
FACS analysis of congenic Thy1.1+ CD45.2+ CXCR4+ c-kit CAR-T cells in recipient PB, spleen, thymus, and lymph nodes 24 
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Figure S5
Expression of CXCL12 (SDF-1, CXCR4 ligand) in mouse whole BM and BM KSL
FACS analysis of mouse whole BM and BM KSL (c-kit+sca1+Lineage‒) for CXCL12 (conjugated with FITC). 
CXCL12 expression was compared with isotype control.














































Gated to live BM KSL
0.0%
0.0%
Gated to live whole BM
